» Articles » PMID: 38666950

Inflammasome Molecular Insights in Autoimmune Diseases

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2024 Apr 26
PMID 38666950
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune diseases (AIDs) emerge due to an irregular immune response towards self- and non-self-antigens. Inflammation commonly accompanies these conditions, with inflammatory factors and inflammasomes playing pivotal roles in their progression. Key concepts in molecular biology, inflammation, and molecular mimicry are crucial to understanding AID development. Exposure to foreign antigens can cause inflammation, potentially leading to AIDs through molecular mimicry triggered by cross-reactive epitopes. Molecular mimicry emerges as a key mechanism by which infectious or chemical agents trigger autoimmunity. In certain susceptible individuals, autoreactive T or B cells may be activated by a foreign antigen due to resemblances between foreign and self-peptides. Chronic inflammation, typically driven by abnormal immune responses, is strongly associated with AID pathogenesis. Inflammasomes, which are vital cytosolic multiprotein complexes assembled in response to infections and stress, are crucial to activating inflammatory processes in macrophages. Chronic inflammation, characterized by prolonged tissue injury and repair cycles, can significantly damage tissues, thereby increasing the risk of AIDs. Inhibiting inflammasomes, particularly in autoinflammatory disorders, has garnered significant interest, with pharmaceutical advancements targeting cytokines and inflammasomes showing promise in AID management.

Citing Articles

Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.

Parvin N, Joo S, Mandal T J Funct Biomater. 2025; 16(1).

PMID: 39852580 PMC: 11766201. DOI: 10.3390/jfb16010024.


Advances in bio-polymer coatings for probiotic microencapsulation: chitosan and beyond for enhanced stability and controlled release.

Edo G, Mafe A, Razooqi N, Umelo E, Gaaz T, Isoje E Des Monomers Polym. 2025; 28(1):1-34.

PMID: 39777298 PMC: 11703421. DOI: 10.1080/15685551.2024.2448122.


Innovative mRNA Vaccine Approaches in Targeting Atherosclerosis: A New Era in Cardiovascular Therapy.

Kumar R, Krishnaperumal G, Vellapandian C Cureus. 2024; 16(11):e74141.

PMID: 39712846 PMC: 11662511. DOI: 10.7759/cureus.74141.


Angiotensin-Converting Enzyme-2 (ACE2) Downregulation During Coronavirus Infection.

Nor Rashid N, Amrani L, Alwan A, Mohamed Z, Yusof R, Rothan H Mol Biotechnol. 2024; .

PMID: 39266903 DOI: 10.1007/s12033-024-01277-5.

References
1.
Ghasemi N, Razavi S, Nikzad E . Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017; 19(1):1-10. PMC: 5241505. DOI: 10.22074/cellj.2016.4867. View

2.
Govindarajan V, de Rivero Vaccari J, Keane R . Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets. J Neuroinflammation. 2020; 17(1):260. PMC: 7469327. DOI: 10.1186/s12974-020-01944-9. View

3.
Kahlenberg J, Carmona-Rivera C, Smith C, Kaplan M . Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol. 2012; 190(3):1217-26. PMC: 3552129. DOI: 10.4049/jimmunol.1202388. View

4.
Cookson B, Brennan M . Pro-inflammatory programmed cell death. Trends Microbiol. 2001; 9(3):113-4. DOI: 10.1016/s0966-842x(00)01936-3. View

5.
Wu X, Li K, Yang H, Yang B, Lu X, Zhao L . Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis. J Autoimmun. 2019; 106:102336. DOI: 10.1016/j.jaut.2019.102336. View